Dissolution comparisons using a Multivariate Statistical Distance (MSD) test and a comparison of various approaches for calculating the measurements of dissolution profile comparison
- 721 Downloads
The f 2 test is generally used for comparing dissolution profiles. In cases of high variability, the f 2 test is not applicable, and the Multivariate Statistical Distance (MSD) test is frequently proposed as an alternative by the FDA and EMA. The guidelines provide only general recommendations. MSD tests can be performed either on raw data with or without time as a variable or on parameters of models. In addition, data can be limited—as in the case of the f 2 test—to dissolutions of up to 85% or to all available data. In the context of the present paper, the recommended calculation included all raw dissolution data up to the first point greater than 85% as a variable—without the various times as parameters. The proposed MSD overcomes several drawbacks found in other methods.
KEY WORDSdissolution multivariate statistical difference MSD Weibull f2
The authors thank Vinod P. Shah (Pharmaceutical Consultant, North Potomac, MD, USA) for his great discussions during the development of this work.
Compliance with Ethical Standards
All R codes provided are non-validated and only given as example of algorithm that could be used.
- 3.U.S. Food and Drug Administration. Guidance for industry dissolution testing of immediate release solid oral dosage forms. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). August 1997; http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070237.pdf Accessed 15 Feb 2016.
- 4.U.S. Food and Drug Administration. Guidance for industry: immediate release solid oral dosage forms. Scale-up and post-approval changes: chemistry, manufacturing and controls, in vitro dissolution testing, and in vivo bioequivalence documentation [SUPAC-IR]. November 1995; http://www.fda.gov/downloads/Drugs/.../Guidances/UCM070636.pdf Accessed 15 Feb 2016.
- 5.European Medicines Agency. CPMP/EWP/QWP/1401/98 Rev. 1 Committee for Medicinal Products for Human Use (CHMP). 2010; Guideline on the Investigation of Bioequivalence. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf (2010) Accessed 15 Feb 2016.
- 11.Gomez-Mantilla JD, Casabo VG, Schaefer UF, Lehr CM. Permutation test (PT) and tolerated difference test (TDT): two new, robust and powerful nonparametric tests for statistical comparison of dissolution profiles. Int J Pharm. 2013;441(1–2):458–67. doi: 10.1016/j.ijpharm.2012.11.008.CrossRefPubMedGoogle Scholar
- 13.Hogarty K, Ferron J, Hess M, Kromrey J A Macro for computing point estimates and confidence intervals for Mahalanobis distance, Paper 163–30, SUGI 30, Philadelphia, Pennsylvania, 2005, http://www2.sas.com/proceedings/sugi30/163-30.pdf, accessed July 20, 2016
- 15.Ma MC, Lin RP, Liu JP. Statistical evaluations of dissolution similarity. Stat Sin. 1999;9(4):1011–27.Google Scholar
- 16.Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol. 1996;20(6):64–74.Google Scholar
- 21.Tsong Y, Hammerstrom T, Sathe P, Shah V. Statistical assessment of mean differences between two dissolution data sets. Drug Inf J. 1996;30(4):1105–12.Google Scholar
- 24.Wicklin R. What is Mahalanobis distance? http://blogs.sas.com/content/iml/2012/02/15/what-is-mahalanobis-distance.html, accessed July 23rd, 2016